<DOC>
	<DOCNO>NCT00140348</DOCNO>
	<brief_summary>The purpose study evaluate clinical laboratory safety patient receive 4 different dos GVAX® Prostate Cancer Vaccine order determine maximum tolerate dose .</brief_summary>
	<brief_title>Dose Escalation Efficacy Trial GVAX® Prostate Cancer Vaccine</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Diagnosis adenocarcinoma prostate Metastatic prostate cancer deem unresponsive refractory hormone therapy Detectable metastasis ECOG performance status 0 1 Transitional cell , small cell , neuroendocrine , squamous cell prostate cancer Significant cancer relate pain Prior gene therapy , chemotherapy , immunotherapy</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>Prostate</keyword>
	<keyword>Cancer</keyword>
	<keyword>Advanced Prostate Cancer</keyword>
	<keyword>Metastatic</keyword>
	<keyword>Hormone-refractory</keyword>
	<keyword>GVAX</keyword>
	<keyword>Vaccine</keyword>
	<keyword>Allogeneic cell</keyword>
</DOC>